WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 8, 650-664. Review Article ISSN 2277–7105

FORMULATION AND EVALUATION OF AN ANTIFUNGAL PAPER STRIP

Mr. Shubham Shirsath*, Mr. Kshitij Varma, Mr. Bhushan Shirsath, Mr. Rushikesh Sonawane, Mr. Vedant Sonawane, Miss Siddhi Sonawane, Miss Sapana Sonawane

India.

Article Received on
26 February 2025,

Revised on 19 March 2025,
Accepted on 08 April 2025

DOI: 10.20959/wjpr20258-36304

***Corresponding Author**
Shubham Shirsath
India.

1. ABSTRACT

In recent years, fungal infections have become an increasingly significant global health concern. This rise in prevalence is partly due to the growing number of immunocompromised patients, the widespread use of antimicrobial, and environmental changes that promote fungal proliferation. Fungal pathogens, such as *Candida*, *Aspergillus*, and *Trichophyton*, are responsible for a wide range of infections, including superficial skin conditions, systemic infections, and mucosal infections. Traditional treatment approaches often face limitations due to issues like poor bioavailability, drug resistance, and side effects associated with oral or systemic antifungal agents. Therefore, there is a growing demand for innovative drug delivery systems that can improve the efficacy of antifungal treatments while minimizing these issues. One promising strategy is the use of novel drug delivery systems that not only improve the localized delivery of antifungal agents but also ensure sustained and controlled release to enhance therapeutic outcomes. In this context, the development of a paper strip-based antifungal dosage form has been explored as an effective alternative to conventional dosage forms such as creams, ointments, or oral tablets.

KEYWORDS: Stone flower, Pharmacological profile, phytochemical aspects, phytoconstituent.

2. INTRODUCTION



Fig. 2.1: Mechanism of fungal infection.

Fungal infection

(1) stimulates the arrival of monocytes at the site of infection

(2) Which subsequently mature into monocyte-derived dendritic cells (moDCs). Depending on local environmental host and pathogen factors, these moDCs can develop into either inflammatory DCs (inf-DCs; 3a) or immunomodulatory DCs (imo-DCs; 3b), which subsequently direct the immune response. Inf-DCs promote sterilizing immunity characterized by interferon gamma (IFNγ)- producing Th1 cells, interleukin (IL)-17-producing Th17 cells, and " classically activated " exudate macrophages (ExMs; 4a). Imo-DCs promote fungal persistence characterized by IL-10-producing Treg cells, IL-4-, IL-5, and IL-13-producing Th2 cells, and "alternatively-activated" exudate macrophages (4b).[1,2]

❖ **Rising Cases of Fungal Infections, Especially in Immunocompromised Patients**

Fungal infections have become an increasing public health concern, particularly among immunocompromised individuals. These infections, which were once considered relatively rare or confined to specific populations, now affecting a broader range of patients, including those with.[3]

- HIV/AIDS
- Cancer patients undergoing chemotherapy
- Organ transplant recipients
- People with diabetes or chronic respiratory diseases
- Patients on long-term immunosuppressive therapy

Immunocompromised patients are particularly vulnerable to fungal infections because their immune systems are unable to mount an effective defense. As a result, opportunistic fungi that are typically harmless in healthy individuals can cause serious, life-threatening infections in these populations. Some of the most common fungi responsible for infections include *Candida* species (e.g., *Candida albicans*), *Aspergillus* species (e.g., *Aspergillus fumigatus*), and *Mucor* species (which cause mucormycosis).[4,5]

❖ **Key Factors Behind the Rise in Fungal Infections**

1. **Increased Use of Immunosuppressive Drugs**: Drugs like corticosteroids, chemotherapy agents, and immunosuppressive drugs for organ transplants lower the body's ability to fight off fungal infections.[6]
2. **Prevalence of Chronic Diseases**: Diabetes and other metabolic disorders, which can alter immune responses and provide an environment conducive to fungal growth, are becoming more common.[7]
3. **Improved Diagnostic Methods**: Advances in fungal infection diagnostics, such as PCR-based techniques and imaging, have led to better detection, but they also reveal more cases that were previously undiagnosed.[8]
4. **Climate Change**: Changes in climate, including rising temperatures and humidity, may expand the range of certain fungi, leading to more frequent environmental exposure and infection.[9]

❖ **Limitations of Current Antifungal Treatments**

The treatment of fungal infections, particularly in immunocompromised patients, faces several significant challenges. Some of the major limitations of current antifungal therapies include:

1. **Systemic Toxicity**

- Amphotericin B (often considered the "gold standard" for severe systemic fungal infections) is highly effective but has serious systemic side effects, including kidney

toxicity. This limits its use, especially in patients who may already be experiencing renal issues due to their underlying condition or treatment regimen.[10]

- Voriconazole**,** another broad-spectrum antifungal, has been associated with liver toxicity and visual disturbances. These side effects may require close monitoring and dose adjustments.[11]
- Flucytosine, used in combination with other antifungals for certain infections like cryptococcal meningitis, can cause bone marrow suppression and liver dysfunction.[12]
- Systemic antifungal agents can lead to cumulative toxicity over prolonged periods, especially in critically ill or elderly patients who may have impaired organ function.[13]

2. Poor Bioavailability

- Many antifungal agents suffer from poor oral bioavailability, meaning that they are not efficiently absorbed into the bloodstream when taken orally. This is particularly true for drugs like Itraconazole, which can have variable absorption, and for Griseofulvin, which is often ineffective for deep or invasive fungal infections because it is poorly absorbed from the gastrointestinal tract.[14]
- As a result, many antifungal treatments require intravenous administration, which is not always feasible for long-term therapy, especially in outpatient settings or in patients with limited access to healthcare.[15]

3. Narrow Spectrum and Limited Effectiveness

- While azole antifungals (e.g., fluconazole, voriconazole) are effective against certain fungal pathogens, they have limited efficacy against others. For example, azoles are not effective against Mucorales**,** which cause mucormycosis, a rapidly progressing and often fatal infection in immunocompromised patients.
- Echinocandins (e.g., caspofungin, micafungin) are useful for treating *Candida* infections but have limited activity against molds like *Aspergillus*.
- This narrow spectrum of activity can make treatment more complicated, especially when the causative fungal pathogen is not initially identified or when the infection is polymicrobial (involving multiple fungal species).[16]

4. Development of Resistance

- Antifungal resistance is an emerging problem, particularly with *Candida* species. Strains

of *Candida albicans* and other species have developed resistance to azoles (e.g., fluconazole), making treatment more difficult and leading to treatment failures in some cases.

- Resistance to echinocandins has also been documented, though it is less common. The rise in resistance is linked to overuse and misuse of antifungal drugs, particularly in hospitals and long- term care settings.[17]

5. Limited Options for Severe or Rare Infections

- For certain severe fungal infections, especially those caused by less common pathogens like Mucorales (causing mucormycosis) or Histoplasma capsulatum, there are few effective treatment options. While liposomal amphotericin B may be used, it's not always effective, and there is a lack of FDA-approved drugs for these infections.[18]
- Invasive fungal infections of the central nervous system (e.g., cryptococcal meningitis) require prolonged therapy with antifungal agents that may have limited penetrance into the brain, leading to suboptimal treatment outcomes.[19]

6. Biodegradability and Sustainability

- Paper, as a naturally occurring material, is biodegradable and can be produced from renewable sources, making paper strips a more environmentally friendly alternative to plastic-based dosage forms. This aspect of sustainability aligns with growing concerns about the environmental impact of pharmaceutical packaging and waste, thus offering a greener solution for drug delivery systems.[20]
- By using paper as the primary substrate, paper strip formulations could potentially reduce the carbon footprint associated with drug packaging, offering an eco-conscious alternative in an era of growing environmental awareness.[21]

❖ **Justification for Paper Strip Dosage Form**

Paper strips, as an innovative dosage form, offer several key advantages for drug delivery that make them a promising alternative to conventional forms like tablets, capsules, or liquid formulations. Below is an expanded explanation of their benefits:

1. **Flexibility and Lightweight -** Paper strips are inherently flexible and lightweight, making them easy to handle, store, and transport. This versatility also allows for customization in terms of shape, size, and thickness to suit various therapeutic needs. Their portability and minimal weight make them an ideal option for patients on the go, particularly for

paediatric, geriatric, or non-compliant patients who may struggle with swallowing traditional dosage forms.[22]

2. **Ease of Customization -** The paper matrix can be tailored to meet specific drug delivery needs. For example, drug content, release rates, and even the addition of excipients can be adjusted to optimize the therapeutic effect. Paper strips can be printed or coated with active pharmaceutical ingredients (APIs) in precise doses, allowing for highly controlled and targeted drug delivery. This customization is especially beneficial in personalized medicine, where treatment plans are becoming more individualized. [23]

3. **Sustained and Controlled Drug Release -** One of the most significant advantages of paper strips is their potential to deliver drugs in a sustained, controlled manner. Paper is a porous material that can be designed to release drugs over extended periods, thereby providing a continuous therapeutic effect. This could minimize the need for frequent dosing, improving patient compliance and convenience. The rate of drug release can be tailored by adjusting the formulation, such as through the use of polymers or other substances embedded within the paper to modulate the release kinetics.[24]

4. **Minimal Side Effects and Improved Efficacy -** Because paper strips can offer controlled release, they help maintain therapeutic drug concentrations in the bloodstream over a longer period. This results in a reduction in the fluctuations of drug levels typically seen with immediate-release formulations, which can help minimize side effects such as peaks in plasma concentration that cause adverse reactions. The consistent delivery of the drug can lead to better efficacy and potentially reduce the likelihood of drug toxicity or under-dosing.[25]

5. **Patient-Friendly and Non-Invasive Delivery –** Paper strips can be designed for various routes of administration, such as oral or transdermal delivery. For oral use, the strip dissolves or disintegrates in the mouth, offering an easy-to- administer alternative for individuals who have difficulty swallowing pills. Transdermal strips could allow for drug absorption through the skin, providing an alternative to injections and enhancing patient comfort. The non-invasive nature of these delivery systems is a significant advantage, especially for children, elderly individuals, and those with chronic conditions who require long-term therapy.[26]

3. AIM AND OBJECTIVE AIM

To formulate and evaluate a novel antifungal paper strip for localized delivery, minimizing systemic side effects and enhancing antifungal efficacy.

Objectives

- To prepare a paper strip dosage form with an incorporated antifungal agent.
- To evaluate the physicochemical characteristics of the paper strip, including tensile strength, folding endurance, and thickness.
- To perform in vitro release studies to determine the release profile of the antifungal agent from the strip.
- To assess the antifungal efficacy of the formulation against common fungal pathogens.

4. METHODOLOGY

❖ **Key Components of Antifungal Paper Strips**

The formulation of antifungal paper strips involves several important components to ensure the efficacy, stability, and controlled release of the active ingredient.

4.1 Active Ingredient: The choice of antifungal agent depends on the type of fungal infection being targeted. Common antifungal agents that can be used in these strips include:

- **Azoles** (e.g., fluconazole, ketoconazole)
- **Allylamines** (e.g., terbinafine)
- **Polyenes** (e.g., nystatin, amphotericin B)
- **Echinocandins** (e.g., caspofungin, micafungin)
- **Griseofulvin** or **Tolnaftate** (for dermatophyte infections[27]

4.2 Paper Base Material: The base material of the strip is typically a thin, porous paper or fabric- like substrate that can hold the active drug while still allowing for diffusion. Materials like cellulose-based paper, non-woven fabrics, or biopolymer-based materials can be used.[28]

4.3 Polymeric Matrix: To ensure the sustained release of the antifungal agent, the paper can be impregnated with a polymeric matrix. Polymers like hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), or Carbopol may be used to form the matrix and control the drug release rate.[29]

4.4 Plasticizers and Stabilizers: To enhance the flexibility and stability of the paper strip, plasticizers (e.g., glycerine, propylene glycol) and stabilizers (e.g., antioxidants) may be incorporated into the formulation. These ingredients also help prevent the degradation of the active drug over time.[30]

4.5 Adhesives: If the strip is intended for direct application to the skin or mucous membrane, it may be coated with an adhesive layer (e.g., polyvinyl alcohol, acrylates) to ensure proper adhesion without causing irritation or discomfort.[31]

4.6 Preservatives: If the formulation contains water or is susceptible to microbial contamination, preservatives like benzalkonium chloride or phenoxyethanol may be added to ensure the stability and shelf-life of the product.[32]

❖ METHOD

1. Selection of Antifungal Agent

The first step is selecting a suitable antifungal drug. The antifungal agent should be active against the targeted pathogen, stable during storage, and easily incorporated into the formulation. Some common antifungal agents include:

- **Clotrimazole**
- **Miconazole**
- **Ketoconazole**
- **Fluconazole**
- **Terbinafine**[33]

2. Paper Substrate Selection

The paper used for the dosage form should have specific properties to support the drug, such as:

- **Porosity**: Ensures controlled release of the drug.
- **Biocompatibility**: Non-toxic and non-irritating to the skin or mucosal membranes.
- **Strength**: It should not tear easily when handled.
- **Absorbency**: Helps retain the antifungal agent for sustained release.
- **Ease of handling**: Should be easy to apply to the site of infection.

Common substrates could be **filter paper**, **blotting paper**, or **hydrocolloid paper**, depending on the desired release profile and therapeutic application.[34]

3. Formulation of Drug Solution

To incorporate the antifungal agent into the paper substrate, it must first be dissolved or dispersed in a suitable solvent. The solvent should have the following properties:

- Solubility for the antifungal agent
- **Non-toxic:** to the skin and tissues
- **Volatility**: Should evaporate after the drug is absorbed by the paper, leaving only the active compound.

The typical formulation includes

- **Antifungal drug** (e.g., Clotrimazole, Miconazole)
- **Solvent** (e.g., ethanol, water, glycerin, or a mixture)
- **Polymeric excipients**: These are often included to improve adhesion to the paper and enhance controlled release. Examples include hydroxypropyl methylcellulose (HPMC)**,** polyvinyl alcohol (PVA)**,** or carbopol**.**
- **Plasticizers**: These improve flexibility, such as glycerin or propylene glycol.[35]

4. Impregnation of Paper Strips

Once the drug solution is prepared, the paper strips are impregnated with the drug solution via:

- **Dipping method**: The paper strips are immersed in the antifungal solution for a specified period, followed by removal and drying.
- **Spraying method**: The drug solution is sprayed onto the surface of the paper strip and allowed to dry.
- **Printing method**: The drug solution can also be printed directly onto the paper using inkjet or screen-printing techniques.

The amount of drug loaded onto the paper strip can be controlled by adjusting the concentration of the drug in the solution and the immersion time.[36]

5. Drying Process

After impregnation, the paper strips must be dried to remove the solvent and leave behind the active drug. This is typically done using:

- Air drying
- **Vacuum drying**
- **Freeze-drying (lyophilization)**, depending on the stability of the drug and

formulation.[37]

6. Characterization of Paper Strips

Once the paper strips are dried, the following tests and characterizations should be performed:

- **Drug content uniformity**: Ensures that each strip contains the intended amount of the active drug.
- **Release profile**: Conduct in vitro studies to evaluate how the drug is released from the paper strip over time. This can be done using a dissolution test in appropriate media (e.g., PBS, simulated skin conditions).
- **Mechanical properties**: Evaluate the tensile strength and flexibility of the paper strip to ensure it is easy to handle and apply without breaking.
- **Surface morphology**: Microscopic analysis can be used to observe the uniformity of the drug coating on the paper.
- **Sterility and microbial testing**: The strips should be sterile to prevent contamination and ensure they are safe for topical use.[38]

7. Packaging and Storage

The final paper strips should be packaged in airtight, moisture-proof packaging to prevent degradation or loss of activity. Common packaging materials include:

- **Blister packs**
- **Foil pouches**
- **Plastic containers**

The strips should be stored in a cool, dry place, away from light, and should have an appropriate shelf life based on stability testing.[39]

5. EVALUATION

1. Physical and Chemical Evaluation

- **Thickness and Integrity**: Assess the physical properties of the paper strip, including thickness, flexibility, and tensile strength. The strip should be thin but durable enough to handle without breaking under normal conditions.
- **Active Ingredient Loading**: Quantify the amount of antifungal agent incorporated into the paper strip to ensure the correct dose is available for therapeutic effectiveness.
- **Uniformity**: Ensure that the distribution of the antifungal agent is uniform across the strip

to guarantee consistent dosing.

- **Drug Release Profile**: Evaluate the release rate of the antifungal agent from the paper strip in simulated biological environments (e.g., skin, mucosal surfaces). This can be assessed using dissolution testing in-vitro.[40]

2. **Efficacy Testing**

- **In Vitro Testing**
  - **Minimum Inhibitory Concentration (MIC)**: Determine the MIC of the antifungal agent on common fungal pathogens like *Candida spp.*, *Aspergillus spp.*, or *Dermatophytes*.
  - **Zone of Inhibition**: Test the paper strips against fungal cultures to measure the size of the inhibition zone, which indicates the effectiveness of the antifungal agent.
  - **Time-Kill Assay**: Evaluate how quickly the paper strips can reduce the fungal load over time under controlled conditions.
- **In Vivo Testing** (if applicable):
  - **Animal Models**: Use animal models (e.g., mice or rabbits) with fungal infections to test the therapeutic efficacy of the paper strips. This could involve applying the paper strips to infected skin or mucosal tissues and observing the reduction in fungal load.
  - **Clinical Trials**: Conduct human clinical trials to assess safety and efficacy. These would be essential to determine the real-world effectiveness of the paper strip, including patient compliance, ease of use, and overall treatment success.

3. **Stability Testing**

- **Shelf Life**: Evaluate the stability of the paper strip under various storage conditions (e.g., temperature, humidity). This is important to determine if the antifungal agent remains potent over time.
- **Packaging**: Investigate the packaging system to ensure it protects the paper strips from moisture, light, and other environmental factors that could degrade the active ingredient.
- **Degradation Studies**: Conduct studies to ensure that the paper strip does not degrade prematurely, which could lead to a loss of drug activity.

4. **Safety and Toxicity**

- **Skin Irritation and Sensitization**: Perform dermatological testing on the paper strips to ensure they do not cause skin irritation or allergic reactions when applied topically.
- **Cytotoxicity**: Assess the cytotoxicity of the antifungal agent when applied directly to

cells (e.g., keratinocytes, fibroblasts) to ensure no adverse effects on skin cells.

- **Systemic Toxicity**: Although unlikely with topical use, systemic toxicity testing is necessary if there is any risk of absorption of the antifungal agent.[41]

6. CONCLUSION

- The development of a paper strip as a novel antifungal dosage form holds great potential to improve the management of superficial fungal infections. By offering a localized, non-invasive, and cost-effective treatment option, paper strips could enhance patient compliance and provide more efficient therapy.
- However, careful formulation, extensive evaluation, and clinical testing are essential to ensure the safety, stability, and effectiveness of this novel dosage form. As research progresses, paper strips may become an integral part of the therapeutic armamentarium for treating fungal infections.

7. REFRENCES

1. Jenks JD, Prattes J, Wurster S, Sprute R, Seidel D, Oliverio M, Egger M, Del Rio C, Sati H, Cornely OA, Thompson GR, Kontoyiannis DP, Hoenigl M. Social determinants of health as drivers of fungal disease. *eClinicalMedicine*, 2023; 66: 102325.
2. Hoenigl M, Egger M, Price J, Krause R, Prattes J, White PL. Metagenomic next-generation sequencing of plasma for diagnosis of COVID-19-associated pulmonary aspergillosis. *J Clin Microbiol*, 2023; 61: e0185922.
3. Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J., et al. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. *Antibiotics*, 2020; 9: 877. doi: 10.3390/antibiotics9120877
4. Dong, H., & Li, D. "Development of a novel antifungal paper-based sensor for rapid detection of fungal contamination." *Journal of Applied Microbiology*, 2022; 133(2): 234-245. DOI: 10.1111/jam.14934.
5. Kong, F., Xie, X., & Li, S. "Fabrication of antifungal paper strips for effective food packaging." *Journal of Food Science*, 2020; 85(8): 2416-2423. DOI: 10.1111/1750-3841.15288.
6. Shrestha, A., & Rajbhandari, S. "Antifungal Paper Strips for Wound Care Applications: A Review of Recent Innovations." *Materials Science and Engineering C*, 2021; 119: 111685. DOI: 10.1016/j.msec.2020.111685.
7. Zhao, W., Yang, Y., & Wu, J. "Antifungal Paper-Based Sensors for Environmental

Monitoring of Fungal Spores." *Sensors and Actuators B: Chemical*, 2023; 359: 131472. DOI: 10.1016/j.snb.2022.131472.

8. Mittal BM, Saha RN. A Handbook of Cosmetics. 1st ed. Published by M.K Jain for Vallabh Prakashan, New Delhi, 11-20. 2Int J Res Pharm Sci., 2008; 2(3): 525-28.
9. Carr MM, Pryce DM, Ive FA. "Treatment of seborrhoeic dermatitis with ketoconazole: Response of seborrhoeic dermatitis of scalp to topical ketoconazole", Br J Dermatol., 1987; 116; 2: 213-16.
10. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J. & Henderson, G. Rang & Dale's Pharmacology, 9th edition, 2019; 650-665.
11. Brunton, L. L., Chabner, B. A., & Knollmann, B. C. (Eds.). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed., 2018; 1223-1227.
12. Mandell, G. L., Bennett, J. E., & Dolin, R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (9th ed., 2019; 2781-2794.
13. Carter, H. A., & Fisher, D. "Portable hygiene solutions: A study on the efficacy of paper soap." International Journal of Hygiene and Environmental Health, 2019; 222(4): 525-531.
14. Topical Drug Delivery Systems: Challenges and Opportunities" (Journal of Pharmaceutical Sciences, 2019; 108(5): 123-135.
15. Smith, J. A., & Doe, R. P. Formulation and evaluation of antifungal paper soap for localized drug delivery. Journal of Pharmaceutical Innovations, 2023; 42(2), 123-134: 126.
16. Williams, H. L., & Thompson, P. D. Topical drug delivery systems: An overview of formulations and advancements (2nd ed.). Elsevier., 2021; 143.
17. Brunton, L. L., Chabner, B. A., & Knollmann, B. C. (Eds.). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed., 2018; 1555-1567.
18. Hammer, K. A., Carson, C. F., & Riley, T. V. Antifungal activity of essential oils and other plant extracts. Journal of Applied Microbiology, 1999; 86(5): 985–990.
19. Gültekin, B. Clotrimazole and its applications in dermatology. Journal of Dermatological Treatment, 2019; 30(5): 468–475.
20. Duse, L., Tognini, F., & Potenza, R. Ketoconazole: A review of its antifungal activity in dermatology. Drugs, 1998; 56(6): 797–805.
21. Sykes, M. J., & El-Azzouny, M. Miconazole in the treatment of dermatophytosis and fungal infections. Journal of Clinical & Experimental Dermatology Research, 2013; 4(3): 1–6.

22. Saxena, A., & Williams, R. Zinc pyrithione: An effective antifungal agent for treating seborrheic dermatitis and dandruff. International Journal of Dermatology, 2003; 42(5): 111–115.
23. Zong, Y., & Li, Y. Benzalkonium chloride as an antimicrobial agent and its potential uses in skin care. International Journal of Cosmetic Science, 2017; 39(5): 467–474.
24. Y. L. Chen et al., "Sodium Lauryl Sulfate as a Surfactant in Personal Care Products," International Journal of Dermatology, 2019; 58: 1212-1219.
25. L. P. Jones, "Coconut Oil Derivatives in Skin Care: A Review of Their Use and Benefits," Journal of Cosmetic Science, 2016; 67: 213-221.
26. Brown, E., & Martin, J. Key ingredients in soap formulation: Water, glycerin, and pH adjustment. International Journal of Cosmetic Science, 2020; 45(2): 123-130.
27. Miller, H., & Green, L. The role of excipients in soap formulations: Water, glycerin, and pH balance. Journal of Cosmetic Science, 2021; 39(2): 101-110.
28. Smith, T., & Green, C. Step-by-step guide to soap base preparation: Surfactants, pH adjustment, and formulation. Journal of Cosmetic Science, 2021; 48(3): 145-152.
29. Tavakkol, S., et al. "Stability of Active Ingredients in Soap Formulations," Journal of Pharmaceutical Sciences, 2020; 109: 1367-1376.
30. Hernandez, J., et al. "Incorporation of Active Ingredients in Personal Care Products," International Journal of Cosmetic Science, 2020; 42: 410-418.
31. Chen, H., et al. "Development and Formulation of Novel Paper Soap," Journal of Cosmetic Science, 2011; 62: 423-430.
32. Williams, J., et al. "Paper Soap: A Sustainable Approach to Personal Care Products," Journal of Environmental Chemistry, 2016; 45: 225-230.
33. Brown, D., et al. "Optimizing Paper Soap Manufacturing for Maximum Stability," International Journal of Cosmetic Science, 2018; 40: 350-357.
34. Handbook of Cosmetic Science and Technology" – 4th edition, by André O. Barel et al., 312.
35. Barel, A. O., Paye, M., & Maibach, H. I. Cosmetic science and technology: Theoretical principles and applications (4th ed.), 2014; 408-508.
36. American Society for Microbiology. (). Clinical Microbiology Procedures Handbook 3rd ed., 2016; 1412-1450. ASM Press.
37. Raymond, R. L., & Tim, S. (2007). Antimicrobial Testing Protocols 51-75. CRC Press.
38. Vyas, S. P., & Khar, R. K. Transdermal Drug Delivery: Design and Applications. CBS Publishers & Distributors, 2002; 85-125.

39. Barel, A. O., Paye, M., & Maibach, H. I. Cosmetic science and technology: Theoretical principles and applications (4th ed.), 2014; 95-110.
40. Gellman, B. G. M. Toxicology of Cosmetic Ingredients. Springer, 2005; 45-70.
41. Swati jagdale, dhaval bhavsar "Formulation and evaluation of fluconazole soap strips for dermal infection'. International journal of pharmatech research, October 2011.